文献速递呼吸危重症与机械通气

静脉-静脉体外膜氧合治疗急性呼吸窘迫综合征:系统评价与荟萃分析

Venovenous extracorporeal membrane oxygenation for acute respiratory distress syndrome: a systematic review and meta-analysis.
PubMed 文献 · Lancet Respir Med · 2019-01-11

该系统评价与荟萃分析纳入5项研究(共773例成人ARDS患者),其中2项RCT(429例)的汇总分析显示,与常规机械通气相比,静脉-静脉ECMO组60天死亡率显著降低(34% vs 47%;I2=0%),GRADE证据质量为中等。3项研究报告ECMO组大出血发生率为19%(48/251)。

要点

  • ECMO组大出血发生率为19%(48/251),需权衡出血风险。
  • 该结论基于2项RCT的汇总分析,GRADE证据质量为中等。

核心结论

  • 与常规机械通气相比,静脉-静脉ECMO与成人重度ARDS患者60天死亡率降低相关。
  • 静脉-静脉ECMO亦与中等程度的大出血风险相关。

研究设计与样本

  • 系统评价与荟萃分析,检索MEDLINE、Embase和Cochrane数据库,纳入比较常规机械通气联合或不联合静脉-静脉ECMO的RCT和匹配观察性研究。
  • 共纳入5项研究(2项RCT和3项匹配观察性研究),总计773例成人ARDS患者。
  • 主要分析纳入2项RCT共429例患者,主要结局为60天死亡率。
  • 采用逆方差法加权和随机效应模型汇总数据,计算风险比(RR)和95%CI。
  • 使用GRADE指南评价证据质量。

主要发现

  • 该结局的GRADE证据质量等级为中等。
  • 3项研究报告ECMO组大出血发生率,251例中48例(19%)发生大出血。

关键数值与推荐

  • 大出血发生率:ECMO组19%(48/251)。
  • GRADE证据质量:中等(针对60天死亡率结局)。

临床怎么用

  • 在提供静脉-静脉ECMO的中心,对成人重度ARDS进行管理决策时,可考虑静脉-静脉ECMO以降低60天死亡率。
  • 应用时需关注大出血风险(约19%),权衡获益与出血风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Use of extracorporeal membrane oxygenation (ECMO) in adults with severe acute respiratory distress syndrome has increased in the past 10 years. However, the efficacy of venovenous ECMO in people with acute respiratory distress syndrome is uncertain according to the most recent data. We aimed to estimate the effect of venovenous ECMO on mortality from acute respiratory distress syndrome. METHODS: In this systematic review and meta-analysis, we searched MEDLINE (including MEDLINE In-Process and Epub Ahead of Print), Embase and the Wiley search platform in the Cochrane database for randomised controlled trials and observational studies with matching of conventional mechanical ventilation with and without venovenous ECMO in adults with acute respiratory distress syndrome. Titles, abstracts, and full-text articles were screened in duplicate by two investigators. Data for study design, patient characteristics, interventions, and study outcomes were abstracted independently and in duplicate. Studies were weighted with the inverse variance method and data were pooled via random-effects modelling. We calculated risk ratios (RRs) and 95% CIs to summarise results. The primary outcome was 60-day mortality across randomised controlled trials. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) guidelines were used to rate the quality of evidence FINDINGS: We included five studies, two randomised controlled trials and three observational studies with matching techniques (total N=773 patients). In the primary analysis, which included two randomised controlled trials with a total population of 429 patients, 60-day mortality was significantly lower in the venovenous ECMO group than in the control group (73 [34%] of 214 vs 101 [47%] of 215; RR 0·73 [95% CI 0·58-0·92]; p=0·008; I2 0%). The GRADE level of evidence for this outcome was moderate. Three studies included data for the incidence of major haemorrhage in the ECMO group. 48 (19%) of the 251 patients in these three studies had major haemorrhages. INTERPRETATION: Compared with conventional mechanical ventilation, use of venovenous ECMO in adults with severe acute respiratory distress syndrome was associated with reduced 60-day mortality. However, venovenous ECMO was also associated with a moderate risk of major bleeding. These findings have important implications surrounding decision making for management of severe acute respiratory distress syndrome at centres providing venovenous ECMO. FUNDING: None.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Munshi L, Walkey A, Goligher E, et al. Venovenous extracorporeal membrane oxygenation for acute respiratory distress syndrome: a systematic review and meta-analysis. Lancet Respir Med. 2019. PMID: 30642776. doi:10.1016/S2213-2600(18)30452-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。